Latest & greatest articles for fluticasone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluticasone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluticasone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluticasone

81. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study.

Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. 16935686 2006 08 28 2006 09 07 2016 08 03 1474-547X 368 9537 2006 Aug 26 Lancet (London, England) Lancet Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. 754-62 Wheezing and asthma often begins in early childhood, but it is difficult to predict whether (...) to be started early in life. We did a randomised, double-blind, controlled study of inhaled fluticasone propionate 100 mug twice daily in young children who were followed prospectively and randomised after either one prolonged (>1 month) or two medically confirmed wheezy episodes. The dose of study drug was reduced every 3 months to the minimum needed. If the symptoms were not under control by 3 months, open-label fluticasone propionate 100 mug twice daily was added to the treatment. Children were followed

Lancet2006

82. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs

Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs O'Connor R D (...) , Stanford R, Crim C, Yancey S W, Edwards L, Rickard K A, Dorinsky P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of three alternative first-line maintenance treatments for asthma control: fluticasone propionate (100 microg

NHS Economic Evaluation Database.2004

83. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma

Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma O'Connor R D, Nelson H, Borker R, Emmett A, Jhingran P (...) , Rickard K, Dorinsky P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two combination treatments for patients with persistent asthma were examined. One was fluticasone propionate (FP) 100 microg and salmeterol (SAL) 50 microg

NHS Economic Evaluation Database.2004

84. Use of salmeterol/fluticasone combination (seretide) in an asthma clinic: a pragmatic open study from primary care

Use of salmeterol/fluticasone combination (seretide) in an asthma clinic: a pragmatic open study from primary care Use of salmeterol/fluticasone combination (seretide) in an asthma clinic: a pragmatic open study from primary care Use of salmeterol/fluticasone combination (seretide) in an asthma clinic: a pragmatic open study from primary care Clark C E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of a salmeterol-fluticasone combination (Seretide) inhaler for treating asthma. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with asthma who attended a nurse-run asthma clinic in a rural dispensing general practice. Patients

NHS Economic Evaluation Database.2003

85. Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial

Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial Ayres J G, Price M J, Efthimiou (...) J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of fluticasone propionate (FP; 2 puffs of 250 microg twice daily), added to regular bronchodilator therapy for the treatment of chronic obstructive pulmonary disease

NHS Economic Evaluation Database.2003

87. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial.

Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. 14563743 2003 10 17 2003 11 06 2015 11 19 1756-1833 327 7420 2003 Oct 18 BMJ (Clinical research ed.) BMJ Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. 891 To assess the effect of montelukast (...) versus salmeterol added to inhaled fluticasone propionate on asthma exacerbation in patients whose symptoms are inadequately controlled with fluticasone alone. Design and setting A 52 week, two period, double blind, multicentre trial during which patients whose symptoms remained uncontrolled by inhaled corticosteroids were randomised to add montelukast or salmeterol. Patients (15-72 years; n = 1490) had a clinical history of chronic asthma for > or = 1 year, a baseline forced expiratory volume in one

BMJ2003 Full Text: Link to full Text with Trip Pro

88. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study.

Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. 12816824 2003 06 20 2003 07 09 2017 02 19 1756-1833 326 7403 2003 Jun 21 BMJ (Clinical research ed.) BMJ Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. 1367 To explore the efficacy and safety (...) of fluticasone propionate, cream and ointment, applied twice weekly in addition to maintenance treatment with emollients, in reducing the risk of relapse of chronic recurrent atopic dermatitis. Randomised, double blind, parallel group study of 20 weeks' duration. Dermatology outpatient clinics (6 countries, 39 centres). Adult (aged 12-65) patients with moderate to severe atopic dermatitis who were experiencing a flare. Participants applied fluticasone propionate (0.05% cream or 0.005% ointment; once or twice

BMJ2003 Full Text: Link to full Text with Trip Pro

89. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. 12583942 2003 02 13 2003 03 21 2015 11 19 0140-6736 361 9356 2003 Feb 08 Lancet (London, England) Lancet Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. 449-56 Inhaled long-acting beta2 agonists improve lung function and health status in symptomatic chronic obstructive pulmonary disease (COPD (...) ), whereas inhaled corticosteroids reduce the frequency of acute episodes of symptom exacerbation and delay deterioration in health status. We postulated that a combination of these treatments would be better than each component used alone. 1465 patients with COPD were recruited from outpatient departments in 25 countries. They were treated in a randomised, double-blind, parallel-group, placebo-controlled study with either 50 microg salmeterol twice daily (n=372), 500 microg fluticasone twice daily (n

Lancet2003

90. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma

Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two initial maintenance treatments for patients with persistent asthma were examined. Salmeterol-fluticasone propionate (SF; salmeterol 50 microg and fluticasone propionate 100 microg) delivered twice daily via

NHS Economic Evaluation Database.2002

91. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population

Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population Pathak D S, Davis E A, Stanford R H Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology was controller therapy for patients with asthma. The comparators were inhaled corticosteroids and leukotriene modifiers in real world clinical practice. The authors compared fluticasone propionate (44 or 110 microg) with oral zafirlukast (20 mg) and montelukast

NHS Economic Evaluation Database.2002

92. Inhaled fluticasone at different doses for chronic asthma.

Inhaled fluticasone at different doses for chronic asthma. BACKGROUND: Inhaled fluticasone propionate (FP) is a high potency inhaled corticosteroid used in the treatment of asthma. OBJECTIVES: 1. To assess the efficacy and safety outcomes in studies that compared inhaled fluticasone at different nominal daily doses in the treatment of chronic asthma. 2. To test for the presence of a dose response effect. SEARCH STRATEGY: We searched the Cochrane Airways Group Trial Register (1999) and reference (...) lists of articles. We contacted trialists and pharmaceutical companies for additional studies and searched abstracts of major respiratory society meetings (1997-1999). SELECTION CRITERIA: Randomised trials in children and adults comparing fluticasone at different nominal daily doses in the treatment of chronic asthma. Two reviewers independently assessed articles for inclusion and methodological quality. DATA COLLECTION AND ANALYSIS: One reviewer extracted data. Quantitative analyses where

Cochrane2002

93. Fluticasone versus beclomethasone or budesonide for chronic asthma.

Fluticasone versus beclomethasone or budesonide for chronic asthma. BACKGROUND: Beclomethasone dipropionate (BDP) and budesonide (BUD) are commonly prescribed inhaled corticosteroids for the treatment of asthma, Fluticasone propionate (FP) is newer agent with greater potency in in-vitro assays. OBJECTIVES: To compare the efficacy and safety of Fluticasone to Beclomethasone or Budesonide in the treatment of chronic asthma. SEARCH STRATEGY: We searched the Cochrane Airways Group Trial Register (...) (1999) and reference lists of articles. We contacted trialists and pharmaceutical companies for additional studies and searched abstracts of major respiratory society meetings (1997-1999). SELECTION CRITERIA: Randomised trials in children and adults comparing Fluticasone to either Beclomethasone or Budesonide in the treatment of chronic asthma. Two reviewers independently assessed articles for inclusion and methodological quality. DATA COLLECTION AND ANALYSIS: One reviewer extracted data

Cochrane2002

94. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis

Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R Authors' objectives To examine the dose-response relation of inhaled fluticasone propionate (...) in adolescents and adults with asthma. Searching MEDLINE was searched from January 1 1966 to December 1999 with the keyword 'fluticasone'. This search was combined with a search using the MeSH terms 'asthma' and 'chemical and pharmacologic phenomena' or 'dose-response relationship, drug', or the keywords 'dose' or 'dosage'. EMBASE was searched from 1980 to December 1999 using the keywords 'fluticasone' and 'dose' or 'dosage'. Additional studies were identified by contacting the manufacturer of fluticasone

DARE.2001

95. Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus Babyhaler spacer in the treatment of asthma in preschool-aged children

Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus Babyhaler spacer in the treatment of asthma in preschool-aged children Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus Babyhaler spacer in the treatment of asthma in preschool-aged children Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus Babyhaler spacer in the treatment of asthma in preschool-aged children Bisgaard H, Price M J (...) , Maden C, Olsen N A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined fluticasone propionate (FP), administered by a metered-dose inhaler and a Babyhaler spacer device. Type of intervention Secondary prevention

NHS Economic Evaluation Database.2001

96. Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma

Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma Menendez R, Stanford R H, Edwards L, Kalberg C, Rickard K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two drug therapies were compared for the treatment of patients suffering from persistent asthma. The first was an inhaled glucocorticoid, fluticasone propionate (FP), at a dose of 88 microg twice daily. The second was a leukotriene receptor antagonist, zafirlukast (ZA), at a dose of 20 mg twice daily. Salbutamol

NHS Economic Evaluation Database.2001

97. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma

One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma Stempel D A, Meyer J W, Stanford R H, Yancey S W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology under investigation was the use of inhaled corticosteroids (ICSs), specifically fluticasone propionate (FP), in the treatment of asthma. Type of intervention Treatment and secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study

NHS Economic Evaluation Database.2001

98. Comparison of cefuroxime with or without intranasal fluticasone for the treatment of rhinosinusitis. The CAFFS Trial: a randomized controlled trial.

Comparison of cefuroxime with or without intranasal fluticasone for the treatment of rhinosinusitis. The CAFFS Trial: a randomized controlled trial. 11754675 2001 12 28 2002 01 14 2016 11 24 0098-7484 286 24 2001 Dec 26 JAMA JAMA Comparison of cefuroxime with or without intranasal fluticasone for the treatment of rhinosinusitis. The CAFFS Trial: a randomized controlled trial. 3097-105 It is not known whether intranasal corticosteroids are beneficial to treat acute rhinosinusitis in patients (...) at 22 sites (12 primary care and 10 otolaryngology). Two puffs (total dose, 200 microgram) of fluticasone propionate (n = 47) or placebo nasal spray (n = 48) in each nostril once daily for 21 days; all received 2 puffs of xylometazoline hydrochloride in each nostril twice daily for 3 days and 250 mg of cefuroxime axetil twice daily for 10 days. Time to clinical success (patient reported cured or much improved) during telephone follow-up at 10, 21, and 56 days. A total of 88 patients (93%) completed

JAMA2001

99. Inhaled fluticasone propionate for chronic asthma.

Inhaled fluticasone propionate for chronic asthma. BACKGROUND: Inhaled fluticasone propionate (FP) is a relatively new inhaled corticosteroid for the treatment of asthma. OBJECTIVES: 1. To assess efficacy and safety outcomes in studies that compared FP to placebo for treatment of chronic asthma. 2. To explore the presence of a dose-response effect. SEARCH STRATEGY: We searched the Cochrane Airways Group Trial Register (1999), reference lists of articles, contacted trialists and searched

Cochrane2001

100. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma

Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily (...) and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Lundback B, Jenkins C, Price M J, Thwaites R M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Salmeterol/fluticasone propionate combination

NHS Economic Evaluation Database.2000